Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.60 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15241174 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 | |
| SCHEMBL4661857 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 | |
| SCHEMBL313650 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 | |
| SCHEMBL15060852 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 | |
| SCHEMBL4955369 | 1.00 | — | — | |
| SCHEMBL6383256 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 | |
| SCHEMBL6276387 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 | |
| SCHEMBL2456824 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 | |
| SCHEMBL6273599 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 | |
| SCHEMBL15240966 | 1.00 | DNM1 (0.60) | DNM1GBA1TSHRTHRBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3448354-B1 | POST-FOAMING MILD CLEANSING COMPOSITION | PZ CUSSONS INT LTD (GB) | 2025-07-16 | — | — | EP | claimed |
| EP-2373783-B1 | METHOD OF ENHANCING CELL GROWTH USING ALKYL-AMINE-N-OXIDE (AANOX) | Baxalta GmbH (CH) | 2017-11-01 | — | — | EP | claimed |
| EP-2737799-A1 | Biopesticide containing essential oils and process for obtaining the same | SC Amia Sport International SRL (RO) | 2014-06-04 | — | — | EP | claimed |
| JP-4838936-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-7591949-B2 | Method for the improvement of transport across adaptable semi-permeable barriers | IDEA AG (DE) | 2009-09-22 | — | — | US | claimed |
| US-20080311184-A1 | METHOD FOR DEVELOPING, TESTING, AND USING ASSOCIATES OF MACROMOLECULES AND COMPLEX AGGREGATES FOR IMPROVED PAYLOAD AND CONTROLLABLE DE/ASSOCIATION RATES | IDEA AG (DE) | 2008-12-18 | — | — | US | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2001010413-A2 | PERIODIC STRUCTURES COMPRISING LIPIDS, POLYELECTROLYTES, AND STRUCTURES-INDUCING SOLUBLE OLIGOVALENT LINKERS | IDEA AG (DE) | 2001-02-15 | — | — | WO | claimed |
| WO-2001001963-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG (DE) | 2001-01-11 | — | — | WO | claimed |
| WO-2001001962-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG. (DE) | 2001-01-11 | — | — | WO | claimed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | claimed |
| EP-1039880-A1 | METHOD FOR DEVELOPING, TESTING AND USING ASSOCIATES OF MACROMOLECULES AND COMPLEX AGGREGATES FOR IMPROVED PAYLOAD AND CONTROLLABLE DE/ASSOCIATION RATES | Idea Innovative Dermale Applikationen GmbH (DE) | 2000-10-04 | — | — | EP | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| WO-2000024377-A1 | METHOD FOR DEVELOPING, TESTING AND USING ASSOCIATES OF MACROMOLECULES AND COMPLEX AGGREGATES FOR IMPROVED PAYLOAD AND CONTROLLABLE DE/ASSOCIATION RATES | IDEA INNOVATIVE DERMALE APPLIKATIONEN GMBH (DE) | 2000-05-04 | — | — | WO | claimed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | claimed |
| EP-0345246-B1 | Tissue adhesive | IMMUNO AG (AT) | 1993-12-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | DNM1 805/4885GBA1 1678/4885TSHR 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.